Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company announced the completion ...

Capricor Therapeutics (NASDAQ:CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration’s pre-license inspection of its San ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced today that it intends to file a Biologics License Application [BLA] for deramiocel for the treatment of patients with Duchenne Muscular ...

Capricor Therapeutics announced that it has successfully completed the U.S. FDA's Pre-License Inspection of its San Diego manufacturing facility for its lead therapy candidate, Deramiocel ...

Capricor Therapeutics has submitted a Biologics License Application (BLA) to the FDA for deramiocel, an investigational cell therapy intended to treat Duchenne muscular dystrophy (DMD ...

Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for DMD was revealed as the first drug expected to face an FDA advisory ...

In addition, if Capricor were to receive FDA marketing approval for Deramiocel regarding the treatment of DMD, Capricor would be eligible to receive a Priority Review Voucher (PRV) based on its ...

About HOPE-2 Open Label Extension (OLE) Study HOPE-2 was a randomized, double-blind, placebo-controlled, Phase 2 clinical study of Capricor’s lead investigational therapy, deramiocel ...

In addition, if Capricor were to receive FDA marketing approval for deramiocel regarding the treatment of DMD, Capricor would be eligible to receive a Priority Review Voucher (PRV) based on its ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...